Law firm Greenberg Traurig, MassMEDIC and LB Ventures created Medtech Partnering Day with an eye on putting start-ups and medtech titans together in the same room.
You can't do M&A without a little meet & greet.
Here's a look at some of the top mergers & acquisitions stories for medical device companies this week: Medtronic CEO: 'Covidien deal will help us do for ORs what we've done for cath labs'; Medtronic details shareholder votes for Covidien merger; CardioMEMS, Nevro among top 20 VC-backed healthcare exits of 2014; Medtronic-Covidien merger could close this month; Covidien's Stellarex drug-eluting balloon wins CE Mark
Here's a look at some of the top regulatory stories for medical device companies this week: Another recall for Covidien's Nellcor ventilator business; MiMedx reveals subpoena, lawsuit against rival, beefs with FDA; Quanta wins CE Mark for portable dialysis device; Cohera Medical wins approvable letter from FDA for TissuGlu surgical sealant; FDA lifts import ban on Hospira infusion pumps
Medtronic CEO Omar Ishrak highlights how the Covidien buyout will enable his company to expand its value-based model into the operating room.
Almost exactly a year ago Medtronic (NYSE:MDT) CEO Omar Ishrak insisted that value-based healthcare is the salvation, not the damnation, of the medical device industry.
Medtronic and Covidien could close their $43 billion mega-merger by the end of the month, according to a regulatory filing.
Medtronic's shareholders overwhelmingly approved its proposed, $43 billion merger with Covidien this week, including a controversial provision to cover a portion of its executives tax bills.
Covidien's Stellarex drug-eluting balloon, which it's slated to deal to Spectranetics after the closure of its buyout by Medtronic, wins CE Mark approval in the European Union.
European regulators granted market clearance for Covidien's (NYSE:COV) Stellarex drug-eluting balloon for treating peripheral artery disease, the company said today.